Mochida Pharmaceutical Co., Ltd.

Yasushige Akada

Ichiro Yamamoto

Tsutomu Satoh

Yoshitaka Maeda

Tomoyuki Kamino

Manabu Itoh

Kazuyuki Matsuura

Naoto Kosuga

Daido Hotta

Hideharu Uchida

Ken-ichi Amano

Kazuo Kato

Hidenori Mochizuki

Takafumi Mukaihira

Shinichi Ogawa

Fumiaki Yamasaki

Yutaka Miyazaki

Masato Shimojo

Yasunobu Yumiya

Kazuhiro Suzuki

Akihito Shimoi

Ken-Ichi Amano

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; Rrepresents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NOgroup, or the like; Rrepresents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; Xrepresents O, &#x2014;NR&#x2014;, or &#x2014;S(O)r-; Xrepresents a methylene group, O, &#x2014;NR&#x2014;, or &#x2014;S(O)r-; Q&#x2032; represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.

Heterocyclidene acetamide derivative

An agent for preventing/treating respiratory diseases contains, as an active ingredient, a compound represented by following Formula (I): wherein A is a group represented by L-W [wherein L is a bond or CH; and W is O, SOn (wherein n is 0 to 2), or &#x2014;NR&#x2014; (wherein Ris hydrogen or lower alkyl)]; each of Gand Gis (CH)r (wherein r is 0 to 2), provided that when n is 1, Gand Gmay be bridged by lower alkylene; Y is a lower alkylene or (substituted) benzylidene; Z is a bond or O, provided that when Z is a bond, Y may form a 5- or 6-membered ring with carbon on the benzene ring; Ris, for example, NO, a lower alkoxycarbonyl, (substituted) carbamoyl, (protected) hydroxyl group, (protected) carboxyl, or (protected) N-hydroxycarbamoyl; each of Rand Ris hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy or NO; each of Rand Ris, for example, hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy, CN, or lower alkylsulfonyl; and Ris hydrogen or lower alkyl, a salt thereof or a solvate of them. It has excellent antitussive activity when used as an agent for preventing/treating respiratory diseases such as lung cancer, common cold syndrome, pulmonary tuberculosis, pneumonia, acute bronchitis or chronic bronchitis.

Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient

A compound represented by the following Formula (I):(wherein A represents oxygen atom or &#x2014;NR&#x2014; (Rrepresents hydrogen atom or lower alkyl group); Rrepresents nitro group, lower alkoxycarbonyl group, carbamoyl group unsubstituted or mono- or di-substituted by lower alkyl group, unprotected or protected hydroxyl group, unprotected or protected carboxyl group, lower alkyl group substituted by unprotected or protected hydroxyl group, or tetrazolyl group; and Rrepresents hydrogen atom, cyano group or lower alkylsulfonyl group, provided that when A is &#x2014;NR&#x2014;, it is excluded that Rrepresents unprotected or protected hydroxyl group or lower alkyl group substituted by unprotected or protected hydroxyl group) or its salt, and method for producing the compound, and a pharmaceutical composition containing the compound as active ingredient.

4-hydroxypiperidine derivatives having analgesic activity

Agents for treating neuropathic pain

Nerve cell protective agents

Growing community of inventors

Shinjuku-ku, Japan

Yasushige Akada